NEW YORK — ERS Genomics said on Monday that it has nonexclusively licensed its CRISPR-Cas9 patent portfolio to research animal and cell model developer GenOway.
Financial terms of the deal were not disclosed.
"This license from ERS will broaden our CRISPR IP portfolio, and widen our rodent models offering," GenOway CEO Alexandre Fraichard said in a statement. "This will ultimately enable us to pursue our mission of providing the scientific community with scientifically highly relevant preclinical models paired with guaranteed freedom to operate, in particular for commercial applications."
Dublin-based ERS was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. The IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna. The IP is separate from genome editing patents held by the Broad Institute.
Last month, ERS granted a nonexclusive license to the IP to GenScript. Also, in early 2020, Lyon, France-based GenOway extended its nonexclusive license to CRISPR-Cas9 IP held by Merck for applications involving rodent cells or animals.